Lexicon Pharmaceuticals (NASDAQ: LXRX) presented Monday August 31, 2026 at ESC Congress 2026 Munich a post-hoc analysis of the Phase 3 SOLOIST-WHF trial of sotagliflozin (INPEFA, a dual SGLT1/SGLT2 inhibitor) evaluating efficacy and safety across the spectrum of baseline systolic blood pressure in patients recently hospitalized for worsening heart failure. The analysis was simultaneously published in JACC: Heart Failure (DOI 10.1016/j.jchf.2026.103368). Results: sotagliflozin's cardiovascular death and heart-failure-related event reduction was maintained regardless of baseline systolic blood pressure, including in patients with baseline SBP as low as 100 mmHg, without an increase in hypotension or acute kidney injury. The subgroup analysis strengthens the SGLT1/SGLT2 inhibitor commercial case in worsening heart failure where the class has historically been under-utilized due to concerns about hemodynamic tolerability in lower-blood-pressure patients.
Cytokinetics (NASDAQ: CYTK) confirmed Monday August 31, 2026 the peer-reviewed publication of ACACIA-HCM additional analyses in Circulation and MAPLE-HCM in Journal of the American College of Cardiology: Heart Failure, both following the ESC Congress 2026 Late-Breaking Clinical Trial Session presentations Saturday August 29 in Munich. The ACACIA-HCM Circulation paper details cardiac structure and diastolic function improvements from aficamten (Myqorzo) in symptomatic non-obstructive hypertrophic cardiomyopathy (LV mass reduction, LV wall thickness reduction, and LA volume reduction versus placebo at Week 36), supporting the ACACIA-HCM primary readout (KCCQ Clinical Summary Score and peak VO2) that was presented Friday August 28 in the Hot Line Session and published simultaneously in the New England Journal of Medicine. The MAPLE-HCM JACC: Heart Failure paper reports the trial of aficamten versus metoprolol in obstructive HCM. Cytokinetics plans an aficamten sNDA submission in Q4 2026 for the non-obstructive HCM indication.
AstraZeneca (NASDAQ: AZN) and Ionis Pharmaceuticals (NASDAQ: IONS) presented Sunday August 30, 2026 at ESC Congress 2026 Munich the detailed subgroup analyses from the Phase 3 CARDIO-TTRansform trial of Wainua (eplontersen, an antisense oligonucleotide targeting transthyretin) in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). CARDIO-TTRansform did not meet its primary composite endpoint (cardiovascular mortality plus recurrent CV events through 140 weeks) versus placebo. In the prespecified subgroup analysis, patients receiving eplontersen monotherapy achieved a nominally significant hazard ratio of 0.71 versus placebo, while patients on background TTR stabilizer therapy (tafamidis, Vyndaqel/Vyndamax) at baseline showed no treatment effect. The read-out complicates the silencer-plus-stabilizer commercial approach in ATTR-CM that Alnylam's HELIOS-B trial of vutrisiran validated with 28.2% mortality reduction and 32.8% CV event reduction on background tafamidis. AstraZeneca and Ionis will analyze the full dataset to inform next steps in the CARDIO-TTRansform program.
Novo Nordisk (NYSE: NVO) announced at ESC Congress 2026 that its Phase 3 ZEUS trial of ziltivekimab (an anti-IL-6 monoclonal antibody in development for cardiovascular risk reduction in inflammation-driven disease) failed to reduce major adverse cardiovascular events (MACE) versus placebo in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and inflammation (hsCRP ≥2 mg/L). The three-component MACE primary endpoint hazard ratio was 0.99 (95% CI 0.88-1.11), despite confirmed IL-6 pathway engagement (reductions in free IL-6 and hsCRP as expected). Safety was broadly similar between arms though serious infections were more frequent on ziltivekimab (consistent with the IL-6 class). NVO shares fell more than 9% on the readout, deepening the widening H1 2026 GLP-1 revenue gap that already sat at $10.2 billion versus Eli Lilly. Novo has committed to continuing the two other cardiovascular outcomes trials (HERMES in heart failure, ARTEMIS post-acute MI) with H1 2027 readouts. The ZEUS miss casts doubt on the broader thesis of anti-inflammatory cardiovascular risk reduction via IL-6 blockade.
Cytokinetics (NASDAQ: CYTK) presented Saturday August 29, 2026 additional results from the Phase 3 ACACIA-HCM (Myqorzo aficamten for non-obstructive HCM) and MAPLE-HCM trials in a Late-Breaking Clinical Trial Session at ESC Congress 2026 Munich, with simultaneous publications in Circulation and Journal of the American College of Cardiology: Heart Failure. The ACACIA-HCM additional analyses examined improvements in cardiac structure and diastolic function in patients with non-obstructive HCM (LV mass reduction, LV wall thickness reduction, and LA volume reduction versus placebo at Week 36), extending the primary readout (KCCQ Clinical Summary Score and peak VO2) presented in the Hot Line Session Friday August 28 and simultaneously published in NEJM. The follow-up data strengthens the aficamten commercial case for supplemental NDA in Q4 2026 and continues to differentiate the cardiac myosin inhibitor mechanism from mavacamten (Camzyos, Bristol Myers Squibb) which is currently approved only for obstructive HCM.
Alnylam Pharmaceuticals (NASDAQ: ALNY) presented Saturday August 29 and Sunday August 30, 2026 late-breaking prespecified subgroup analyses from the Phase 3 HELIOS-B trial of vutrisiran (AMVUTTRA, an RNAi therapeutic targeting transthyretin for transthyretin amyloidosis with cardiomyopathy, ATTR-CM) at ESC Congress 2026 Munich. Vutrisiran demonstrated consistent clinical benefit across all-cause mortality and recurrent cardiovascular events in patients with or without background tafamidis (the transthyretin tetramer stabilizer marketed as Vyndaqel/Vyndamax by Pfizer). The HELIOS-B trial had documented 28.2% reduction in all-cause mortality and 32.8% reduction in cardiovascular events with vutrisiran plus stabilizer. Additional analyses examined healthy aging, functional capacity, safety, and outcomes by sex. Alnylam also presented Amylo'ExTTRa, a large real-world analysis from the French National Health Data System characterizing the multisystem burden of ATTR-CM beyond cardiac manifestations. Vutrisiran anchors Alnylam's ATTR franchise alongside inclisiran (Leqvio, licensed to Novartis for hypercholesterolemia) and zilebesiran (Phase 3 ZENITH trial in hypertension).
The Factor XIa inhibitor milvexian (an oral small-molecule antithrombotic co-developed by Bristol Myers Squibb (NYSE: BMY) and Janssen) failed to reduce major adverse cardiovascular events versus placebo when added to standard antiplatelet therapy after recent acute coronary syndrome (ACS) in the Phase 3 LIBREXIA ACS trial presented in a Hot Line Session at ESC Congress 2026 Saturday August 29. The primary endpoint (cardiovascular death, myocardial infarction, or ischemic stroke) occurred in 5.4% of the milvexian arm versus 5.1% on placebo. Researchers observed no differences in intracranial or fatal bleeding between arms, addressing safety concerns that have historically constrained anticoagulant use in the post-ACS setting. The LIBREXIA program continues to assess milvexian in stroke and atrial fibrillation. The Factor XIa class as a whole (also including Bayer-Janssen's asundexian and Anthos Therapeutics' abelacimab) has struggled to demonstrate clean cardiovascular benefit at low bleeding cost.
The STAREE trial (a double-blind Australian primary-prevention trial in adults 70 and older) presented Saturday August 29, 2026 at ESC Congress 2026 Munich and simultaneously published in NEJM showed atorvastatin 40 mg daily reduced major cardiovascular events (cardiovascular death, nonfatal myocardial infarction, stroke, or coronary revascularization) by approximately 30% versus placebo over 5.9 years median follow-up in 9,971 participants (mean age 74.7, 52% women). The co-primary endpoint of disability-free survival (survival free of dementia and physical disability) did not reach statistical significance. Muscle, liver, and diabetes-related adverse events were more common on atorvastatin, though serious adverse events were balanced. STAREE addresses a long-standing evidence gap on statin efficacy in older adults without known cardiovascular disease, diabetes, or dementia. Not a peptide, but the trial matters for peptide-industry readers because it reframes the primary-prevention benefit-risk calculus that will need to be modeled for cardiovascular outcome trials of peptide obesity therapies in older populations.
Cytokinetics (NASDAQ: CYTK) presented Friday August 28, 2026 the full results from the Phase 3 ACACIA-HCM trial of Myqorzo (aficamten, a next-generation cardiac myosin inhibitor) in adults with symptomatic non-obstructive hypertrophic cardiomyopathy at the European Society of Cardiology Congress 2026 in Munich, Germany, with simultaneous publication in The New England Journal of Medicine. The trial met both dual primary endpoints with statistically significant improvements from baseline to Week 36 in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and peak oxygen uptake (peak VO2) versus placebo, plus improvements on key secondary endpoints. LVEF <50% occurred in 10% of aficamten patients vs 1% on placebo, with rare treatment interruptions due to LVEF <40% and two serious heart failure adverse events associated with LVEF <50%. Cytokinetics plans to submit a Supplemental New Drug Application in Q4 2026. There are no currently-approved therapies for non-obstructive HCM, and the ACACIA readout positions aficamten as the potential first-in-class treatment for this indication after the July 2026 initial obstructive-HCM approval.